Article
Pharmacology & Pharmacy
Chang Woo Chae, Gee Euhn Choi, Young Hyun Jung, Jae Ryong Lim, Ji Hyeon Cho, Jee Hyeon Yoon, Ho Jae Han
Summary: The study investigates the relationship between hyperglycemia-induced retromer dysfunction and Alzheimer's disease (AD). The researchers found that high glucose down-regulated the vacuolar protein sorting-associated protein 26a (VPS26a) through a methylation pathway, leading to impaired intracellular trafficking and increased AD-like pathology. Restoring VPS26a levels improved cellular transport and decreased levels of amyloid beta (A beta) and phosphorylated tau (p-tau), suggesting that VPS26a plays a role in inhibiting DM-associated AD pathogenesis.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Article
Neurosciences
Amanda Ferreira Neves, Christian Camargo, Courtney Premer, Joshua M. Hare, Bernard S. Baumel, Milena Pinto
Summary: The study demonstrates that the timing and frequency of MSC injections can impact various aspects of AD-like neuropathology in the 3xTg-AD mouse model. Single-dose MSC injections in young mice reduced neuroinflammation, while multiple doses affected beta-secretase cleavage and tau phosphorylation. Multiple-dose MSC injections also showed differing effects on tau phosphorylation at different sites in young and old mice.
EXPERIMENTAL NEUROLOGY
(2021)
Review
Biochemistry & Molecular Biology
Huiqin Zhang, Wei Wei, Ming Zhao, Lina Ma, Xuefan Jiang, Hui Pei, Yu Cao, Hao Li
Summary: Extracellular neuritic plaques and intracellular neurofibrillary tangles, composed of amyloid-beta and phosphorylated tau protein respectively, are hallmark proteins of Alzheimer's disease. The interactions between these proteins have been extensively studied, with A beta accelerating tau phosphorylation, tau mediating A beta toxicity, and potential synergistic effects on microglial cells and astrocytes. Understanding these interactions may lead to new interventions against Alzheimer's disease.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Mohammad Rafi Khezri, Keyvan Yousefi, Negin Mahboubi, Darya Hodaei, Morteza Ghasemnejad-Berenji
Summary: Alzheimer's disease (AD) is a common neurodegenerative disorder worldwide, and its association with diseases like diabetes has been well-studied. Metformin, a medication commonly used for type 2 diabetes, has shown potential disease-modifying effects on various aspects of AD pathophysiology.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Neurosciences
Siwen Li, Chi Him Poon, Zhigang Zhang, Ming Yue, Ruijun Chen, Yalun Zhang, Md. Farhad Hossain, Yining Pan, Jun Zhao, Lei Rong, Leung Wing Chu, Yat Fung Shea, Ekaterina Rogaeva, Jie Tu, Peter St George-Hyslop, Lee Wei Lim, You-Qiang Song
Summary: This study investigates the role of miR-128 in Alzheimer's disease (AD) and its regulatory mechanism. The results suggest that miR-128 inhibits tau phosphorylation and A beta protein accumulation, indicating its potential therapeutic value for AD. The study also reveals a possible mechanism underlying the dysregulation of miR-128 in AD, in which A beta reduces miR-128 expression by inhibiting C/EBP alpha.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Review
Geriatrics & Gerontology
Jiang Chen, Jun-Sheng Chen, Song Li, Fengning Zhang, Jie Deng, Ling-Hui Zeng, Jun Tan
Summary: Decades of research have shown that amyloid-beta (Aβ) plays an undeniable role in the development of Alzheimer's disease (AD). However, the focus on the pathological effects of Aβ may overshadow the significance of its metabolic precursor, amyloid precursor protein (APP), in the occurrence and progression of AD. This review explores the various roles of APP in AD, including its structure, functions, enzymatic processing, and potential therapeutic approaches to targeting APP to ameliorate AD pathologies and halt disease progression.
Article
Neurosciences
Jian-Guo Li, Benjamin E. Blass, Domenico Pratico
Summary: This study assessed the effect of targeting VPS35 after the development of Alzheimer's disease (AD) pathology and memory impairments. The findings showed that treatment with the drug TPT-172 prevented learning and memory decline in AD mice, reduced the levels of amyloid-beta peptides and phosphorylated tau, increased post-synaptic protein levels, and decreased astrocyte activation. These results demonstrate that pharmacologic stabilization of the retromer recognition core is beneficial even after the establishment of the AD-like pathological phenotype.
JOURNAL OF ALZHEIMERS DISEASE
(2023)
Article
Clinical Neurology
Yalun Zhang, Yi Zhang, Yahyah Aman, Cheung Toa Ng, Wing-Hin Chau, Zhigang Zhang, Ming Yue, Christopher Bohm, Yizhen Jia, Siwen Li, Qiuju Yuan, Jennifer Griffin, Kin Chiu, Dana S. M. Wong, Binbin Wang, Dongyan Jin, Ekaterina Rogaeva, Paul E. Fraser, Evandro F. Fang, Peter St George-Hyslop, You-Qiang Song
Summary: Research has shown that the transcription factor PAX6 is increased in Alzheimer's disease, playing a key role in the hyperphosphorylation of tau protein induced by amyloid-beta. Downregulation of PAX6 can protect against amyloid-beta-induced neuronal death. This study provides novel potential targets for pharmaceutical intervention by modulating signaling pathways involving CDK/pRB/E2F1.
Article
Plant Sciences
Caixia Zang, Hui Liu, Junmei Shang, Hanyu Yang, Lu Wang, Chanjuan Sheng, Zihong Zhang, Xiuqi Bao, Yang Yu, Xinsheng Yao, Dan Zhang
Summary: The study demonstrates that GJ-4 improves cognitive deficits in APP/PS1 transgenic mice by reducing A beta levels, inhibiting tau protein phosphorylation, and suppressing neuroinflammatory responses. These findings provide a basis for further development of GJ-4 as a potential treatment for AD.
Article
Neurosciences
Kelly Ceyzeriat, Benjamin B. Tournier, Philippe Millet, Giovanna Dipasquale, Nikolaos Koutsouvelis, Giovanni B. Frisoni, Valentina Garibotto, Thomas Zilli
Summary: This study found that low-dose radiation therapy (LD-RT) reduced amyloid load and possibly neuroinflammation markers in early-stage Alzheimer's disease, but did not impact tauopathy.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Seda Onder, Kevser Biberoglu, Melike Yuksel, Ozden Tacal
Summary: Alzheimer's disease is characterized by amyloid plaques, neurofibrillary tangles, and neuronal loss. Recent studies focus on multi-targeted drug strategies. TBO, a potential candidate, shows promising effects on reducing amyloid levels and decreasing phosphorylated tau.
CHEMICO-BIOLOGICAL INTERACTIONS
(2022)
Review
Cell Biology
Tanzeel Khan, Rashid Waseem, Mohammad Shahid, Jaoud Ansari, Ishfaq Ahmad Ahanger, Imtaiyaz Hassan, Asimul Islam
Summary: Alzheimer's disease is the most prevalent form of dementia, and there is currently no permanent cure. Stem cell therapy has shown promising results in preclinical studies and is being explored as a potential treatment. This article reviews research from the past decade, discusses hypotheses related to the pathology of Alzheimer's disease, and provides an overview of ongoing clinical trials for immunotherapy and stem cell therapy.
AGEING RESEARCH REVIEWS
(2023)
Article
Biochemistry & Molecular Biology
Paige Grant, Jitendra Kumar, Satyabrata Kar, Michael Overduin
Summary: The study investigated the effects of two specific kinase inhibitors for CaMK1D on A beta-mediated toxicity in mouse primary cortical neurons. While these inhibitors were able to prevent A beta-induced tau hyperphosphorylation, they were not able to protect cells from A beta induced toxicity. Further research and development may lead to the potential use of these inhibitors as part of a multi-drug strategy to combat Alzheimer's disease.
Review
Biochemistry & Molecular Biology
Filippa Lo Cascio, Paola Marzullo, Rakez Kayed, Antonio Palumbo Piccionello
Summary: This review highlights recent research on modifying the structure of curcumin to search for new effective therapeutic agents against neurodegenerative diseases, with a particular focus on Alzheimer's disease.
Review
Endocrinology & Metabolism
Haiyang Du, Xiaoyu Meng, Yu Yao, Jun Xu
Summary: GLP-1R agonists, a type of drug used to treat type 2 diabetes, have the potential to reduce inflammation and oxidative stress, provide neurotrophic effects, and decrease the progression of Alzheimer's disease. Further clinical trials are needed to validate their effectiveness.
FRONTIERS IN ENDOCRINOLOGY
(2022)